A Precise Review on Tenofovir Disoproxil Fumarate: An Analytical Profile
Tenofovir Disoproxil Fumarate (TDF) is antiretroviral medicine used treat AIDS as well as chronic Hepatitis-B. TDF is a prodrug of tenofovir and exists as dominant form due to lesser oral bioavailability of parent drug. TDF is now available in a fixed-dose combination with various antiretrovirals like Cobicistat, Efavirenz, Elvitegravir, Emtricitabine, Lamivudine, Rilpivirine, and Nevirapine. Hence, pharmaceutical analysis of TDF and applicability of different analytical methods have gained crucial importance. The present review article assesses the published analytical methods and a variety of approach for investigation of TDF in bulk drug as well as pharmaceutical formulations including combinations. This detailed review includes examination of around eighty analytical methods published during 2008 to 2016 using various techniques which include HPLC, HPTLC, and UV/ Visible-Spectrophotometry. The review also illustrates the scope and limitations of many published analytical methods for analysis of TDF. Such detailed review will be of great help to the researcher who is working on TDF. Miscellaneous methods of rare but unique pharmaceutical distinction have also been given due consideration. The diagrammatic illustrations provide the statistical overview about the various methods referred for analysis of TDF.
 Avihingsanon A., Sophonphan J., Thammajaruk N., Chaihong P., Burger D., Cressey T. R., Ramautarsing R. A., Praditornsilpa K., Avihingsanon Y., Ruxrungtham K. and HIV-NAT 114 study team. (2015). Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand, J. AIDS & Clinical Research, 6(7), 477. https://doi.org/10.4172/2155-6113.1000477
 Patel K. K., Patel A. K., Ranjan R. R., Patel A. R. and Patel J. K. (2010). Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India, Indian J. STD and AIDS, 31(1), 30–34. https://doi.org/10.4103/0253-7184.68998
 Bygrave H., Ford N., van C. G., Hilderbrand K., Jouquet G., Goemaere E., Vlahakis N., Trivino L., Makakole L. and Kranzer K. (2011). Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years, J. AIDS, 56(3), e75-e78. https://doi.org/10.1097/QAI.0b013e3182097505
 The Merck Index, 13 TH Editions, Merck Research Laboratories, Merck and CO., White House Station, NJ, USA, 2001, 1631–1632.
 Kearney B. P., Flaherty J. F. and Shah J.: Tenofovir disoproxil fumarate, Clinical Pharmacokinetics, 2004, 43(9), 595–612. https://doi.org/10.2165/00003088-200443090-00003
 James C. W., Steinhaus M. C., Szabo S. and Dressler R. M. (2004). Tenofovir‐related nephrotoxicity: case report and review of the literature. Pharmacotherapy, The Journal of Human Pharmacology and Drug Therapy, 24(3), 415–418. https://doi.org/10.1592/phco.24.4.415.33182
 www.Gilead.com/pdf/viread_pi.pdf; Gilead Science Inc. Viread, US prescribing information.
 Birkus G., Hitchcock M. J. and Cihlar T. (2002). Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors, Antimicrobial Agents and Chemotherapy, 46(3), 716–723. https://doi.org/10.1128/AAC.46.3.716-723.2002
 Cihlar T., Birkus G., Greenwalt D. E. and Hitchcock M. J. (2002). Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors, Antiviral research, 54(1), 37–45. https://doi.org/10.1016/S0166-3542(01)00210-8
 Porche D. J. (2002). Tenofovir Disoproxil Fumarate (Viread™), Journal of the Association of Nurses in AIDS Care, 13(3), 100–102. https://doi.org/10.1177/10529002013003007
 Fontana R. J. (2009). Side effects of long‐term oral antiviral therapy for hepatitis B, Hepatology, 49(S5), S185-S195. https://doi.org/10.1002/hep.22885
 Rajput J. K., Patil P. H., Surana S. J. and Shirkhedkar A. A. (2015). Analytical Methods for Determination of Muscle Relax-ant Thiocolchicoside in Pharmaceutical Preparations-A Review, Open Pharmaceutical Sciences Journal, 2(1), 43–55. https://doi.org/10.2174/1874844901502010043
 Siddiqui M. R., AlOthman Z. A. and Rahman N. (2013). Analytical techniques in pharmaceutical analysis: A review, Arabian Journal of chemistry, 2–46.
 Sarala K., Subrahmanyam K. V. and Patnaik A. (2014). Method Development and Validation of Tenofovir In Its Bulk Form by Using RP-HPLC, International Journal of Medicine and Nanotechnology, 1(3), 122–126.
 SM M. and Nandedkar M. A. (2009). Determination of Tenofovir Disoproxil Fumarate by a Sensitive Simple Isocratic RP-HPLC Method, J. Ind. Council Chem, 26(1), 67–69.
 Sundar B. S. and Edla S. (2011). Rp-HPLC Method Development and Validation for the Analysis of Tenofovuir in Pharmaceutical Dosage Forms, Journal of Atoms and Molecules, 1(1), 32–40.
 Sharma T., Mishra N., Moitra S. S. and Sankar D. G. (2012). A validated RP-HPLC method for estimation of Tenofovir disoproxil fumarate in bulk and pharmaceutical formulation, Asian Journal of Pharmaceutical and Clinical Research, 5(3), 108–110.
 Balaji M., Srikanth I., Reddy S, H., Krishna G. R., Ramu S., Kumar V. A. (2012). Development and Validationof RP-HPLC Methodfor Quantitative Estimation of Tenofovir Disproxil Fumarate in Bulk and Pharmaceutical Dosage Form. Journal of Pharmacy Research, 5(9), 4692–4694.
 Kandagal P. B., Manjunatha D. H., Seetharamappa J. and Kalanur S. S. (2008). RP‐HPLC Method for the Determination of Tenofovir in Pharmaceutical Formulations and Spiked Human Plasma, Analytical Letters, 41(4), 561–570. https://doi.org/10.1080/00032710801910742
 Sharma T., Mishra N., Moitra S. S. and Sankar D. G. (2010). A validated RP-HPLC method for estimation of Tenofovir disoproxil fumarate in bulk and pharmaceutical formulation, Asian Journal of Pharmaceutical and Clinical Research, 5(3), 108–110.
 Abdelhay M., Gazy A., Shaalan R. and AshourH. (2013). Selective RP-HPLC-DAD method for determination of tenofovir fumarate and emtricitabine in bulk powder and in tablets, Acta Chromatographica, 27(1), 41–54. https://doi.org/10.1556/AChrom.27.2015.1.4
 Lavanya B., Hariprasad P., Venkatapraveen A., Lakshmi D. P. and Ramireddy M. (2012). Simultaneous estimation of emtricitabine and tenofovir disproxilfumarate by HPLC method, Pharmacia Lettre. Scholars Research Library, 4(6), 1855–1862.
 Karunakaran A., Kamarajan K. and Thangarasu V.(2010). A validated RP-HPLC method for simultaneous estimation of emtricitabine and tenofovir disoproxil Fumarate in pure and in tablet dosage form, Pharm Sin, Pelagia Research Library, 1(2), 52–60.
 Dr. Srinivasan R., Mary K. L., Lakshmana G., KumarD. R., Rajini B. (2014). Method development and validation of tenofovir disoprpxilfumarate and emtricitabine in combined tablet dosage form by UVspectrophotometry and RP-HPLC, Int. J. of Pharmacy and Analytical Research, 3(4), 414–421.
 Venkatesh M., Sumanth A. L., M. N., Rao P. V. (2013). Analytical Method Development And Validation Of Simultaneous Estimation Of Tenofovir And Emtricitabine In Bulk And Pharmaceutical Dosageforms By Using RP-HPLC, Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry, 1(2), 60–69.
 Viswanath V., Shanmugasundaram P., Ravichandiran V. (2013). RP-HPLC Method For The Simultaneous Estimation of Tenofovir Disoproxil Fumarate And Emtricitabine in Combined Tablet Dosage Form, International Journal of PharmTech Research, 5(3), 1186–1195.
 Yenumula B. R., Singampalli M, R. and Challa, B, S., (2015). Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Tablet Dosage Form by Reverse Phase High-performance Liquid Chromatography. SOJ Chromatographic Science. 1(1), pp.2–6. https://doi.org/10.15226/2471-3627/1/1/00104
 Sharma, R. and Gupta, P., (2009). Simultaneous Quantification and Validation of Emtricitabine and Tenofovir Disoproxil Fumarate in a Tablet Dosage Form. Eurasian Journal of Analytical Chemistry, 4(3), 276–284.
 Vanitha C., Kumar P. P., Sekhar R. V., Swarnalatha G. and Sekar V. (2014). Simultaneous Estimation Of Emtricitabine And Tenofovir Disoproxil Fumarate In A Tablet Dosage Form By RP-HPLC Method, International Journal of Pharmaceutical Development & Technology, 4(4), 279–283.
 Devanaboyina N., Satyanarayana T. and Rao G. (2012). HPLC method development and validation for simultaneous estimation of tenofovir and emtricitabine in combined pharmaceutical dosage form, International Journal of Research in Pharmaceutical and Biomedical Sciences, 3(1), 361–367.
 Kumar A. K., Chaitanya K. K. and Babu N. S. (2012). Development And Validation of Reverse Phase HPLC Method For Determination of Lamivudine and Tenofovir in Binary Mixture, Journal of Global Trends in Pharmaceutical Sciences, 3(3), 849–852.
 Gorja A. and Bandla, J. (2011). Method development and validation for the simultaneous estimation of Lamivudine and Tenofovir disoproxil fumarate in pharmaceutical dosage forms by RP-HPLC, International Journal of Advanced Research in Pharmaceutical and Biomedical Sciences, 2(1), 22–32.
 Mali A. S., Salunke P. A., Barhate S. D. and Bari M. M. (2015). Simultaneous Determination of Lamivudine and Tenofovir Disproxil Fumarate by UV Spectrophotometric Method, Word journal of Pharmaceutical Research, 4(3), 995–1006.
 Khan A., Rao V. J., Pulla R. P., Kumar S. S. and Sujana K. (2014). Simultaneous Estimation of Emtricitabine, Tenofovir Disoproxil Fumarate And Rilpivirine Hcl In Tablet Dosage Forms By Rp-HPLC, International Journal of Pharmaceutical Research & Analysis, 4(1), 23–30.
 Jayapalu K., Malipeddi H. and Chinnasamy A. (2014). Chromatographic Separation and in Vitro Dissolution Assessment of Tenofovir disoproxil fumarate, Emtricitabine and Nevirapine in a Fixed Dose Combination of Antiretrovirals, Journal of Applied Pharmaceutical Science, (11), 076–080.
 Bhavsar D. S., Patel B. N. and Patel C. N. (2012). RPHPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form, Pharmaceutical methods, 3(2), 73–78. https://doi.org/10.4103/2229-4708.103876
 Raju N. A., Rao J. V., Prakash K. V., Mukkanti K. and Srinivasu K. (2008). Simultaneous estimation of tenofovir disoproxil, emtricitabine and efavirenz in tablet dosage form by RPHPLC, Oriental Journal of Chemistry, 24(2), 645–650.
 Ramaswamy A. and Dhas A. S. A. G.: Developmentand validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz-based on HPLC, Arabian Journal of Chemistry, 2014.
 Prathap B., Dey A. and Rao G. H. S. (2014). Analytical Method Development And Validation Of Invitro Dissolution Studies Of Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate In Pharmaceutical Dosage Form By RP-HPLC, Journal of Global Trends in Pharmaceutical Sciences, 5(2), 515–520
 Bhargavi G. T., Mohammad Y. R. and Reddy Y. (2012). Method Development and Validation of Lamivudine, Tenofovir and Efavirenz in a Combined Dosage Form by RP-HPLC, Journal of Pharmacy Research, 5(12), 711–714.
 Yadav M., Mishra T., Singhal P., Goswami S. and Shrivastav P. S. (2009). Rapid and specific liquid chromatographic-tandem mass spectrometric determination of tenofovir in human plasma and its fragmentation study, Journal of Chromatographic Science, 47(2), 140–148. https://doi.org/10.1093/chromsci/47.2.140
 Rao N., Bathula V. And Devi K. G. (2013). Method Development And Method Validation of Tenofovir In Human K3 Edta Plasma By Lc-Ms/Ms, Pharma Science Monitor, 4(3), 73–76.
 Paliwal N., Jain P., Dubey N., Sharma S., Khurana S. and Paliwal S. K. (2014). A liquid chromatography tandem mass spectrometry-based regulatory compliant method for the determination of tenofovir in human serum, Drug research, 64(06), 306–312.
 Podany A. T., Sheldon C., Grafelman D. and Ohnmacht C. M. (2015). Assay development for determination of tenofovir in human plasma by solid-phase analytical derivatization and LC-MS/MS, Bioanalysis, 7(24), 3085–3095. https://doi.org/10.4155/bio.15.220
 Delahunty T., Bushman L., Robbins B. and Fletcher C. V. (2009). The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards, Journal of Chromatography B, 877(20), 1907–1914. https://doi.org/10.1016/j.jchromb.2009.05.029
 Zheng J. H., Guida L. A., Rower C., Castillo- Mancilla J., Meditz A., Klein B., Kerr B. J., Langness J., Bushman L., Kiser J. and Anderson P. L. (2014). Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC–MS/MS, Journal of pharmaceutical and biomedical analysis, 88, 144–151. https://doi.org/10.1016/j.jpba.2013.08.033
 Matta M. K., Burugula L., Pilli N. R., Inamadugu J. K. and Jvln S. R. (2012). A novel LC‐MS/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetic study, Biomedical Chromatography, 26(10), 1202–1209. https://doi.org/10.1002/bmc.2679
 Patel A., Patel A. And Makwana A. (2015). Development And Validation Of An Accurate And Precise Lc-Ms/Ms Method for Determination of Tenofovir And Emtricitabine in Human Plasma, International Journal Of Pharmaceutical, Chemical & Biological Sciences, 5(1), 372–380.
 Gomes N. A., Vaidya V. V., Pudage A., Joshi S. S.and Parekh S. A. (2008). Liquid chromatography– tandem mass spectrometry (LC–MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study, Journal of Pharmaceutical and Biomedical Analysis, 48(3), 918–926. https://doi.org/10.1016/j.jpba.2008.07.022
 Valluru R. K., Kumar P. and Kilaru N. B. (2013). High throughput LC–MS/MS method for simultaneous determination of tenofovir, lamivudine and nevirapinein human plasma, Journal of Chromatography B, 931, 117–126. https://doi.org/10.1016/j.jchromb.2013.05.008
 Pradeep K., Dwivedi S. C. and Ashok K. (2011). Validated HPTLC method for the determination of tenofovir as abulk drug and in pharmaceutical dosage form, Res J Chem Sci, 1(7), 33–37.
 Mardia R. B., Suhagia B. N., Pasha T. Y., Chauhan S. P. and Solanki S. (2012). Development and Validation of HPTLC Method for Estimation of Tenofovir Disoproxil Fumarate in Tablet Dosage Form, Journal of pharmaceutical science and bioscientific research, 2(2), 73–76.
 Joshi M., Nikalje A. P., Shahed M. and Dehghan M. (2009). HPTLC method for the simultaneous estimation of emtricitabine and tenofovir in tablet dosage form, Indian Journal of Pharmaceutical Sciences, 71(1), 95–97. https://doi.org/10.4103/0250-474X.51951
 Rao J., Gondkar S. and Yadav S. (2011). Simultaneous HPTLC–Densitometric analysis of Tenofovir and Emtricitabine in Tablet dosage form, Int J Pharm Tech Res, 3(3), 1430–1434.
 Saminathan J. and Vetrichelvan T. (2016). Development and Validation of HPTLC Method for Simultaneous Estimation of Emtricitabine, Rilpivirine and Tenofovir Disoproxil. Fumarate in Combined Dosage form, Bangladesh Pharmaceutical Journal, 19(1), 114–121. https://doi.org/10.3329/bpj.v19i1.29247
 Havele S. and Dhaneshwar S. R. (2012). Development and validation of a stability-indicating lc method for the determination of tenofovir disoproxil fumarate in pharmaceutical formulation, Songklanakarin Journal of Science and Technology, 34(6), 612–622.
 Hussen S. S., Shenoy P. and Krishna M. (2013). Development and validation of stability indicating RPHPLC method for tenofovir nanoparticle formulation, Int. J. Pharm. Pharm. Sci, 5(2), 245–248.
 Agashe M., Chaudhari R., Shirsat V. (2015). A Rapid Stability Indicating RP-HPLC Method and the Degradation Kinetics Data for the Simultaneous Estimation of Tenofovir Disoproxil Fumarate and Emtricitabine, Human Journals Research Article, 3(3), 145–159.
 Prasad L. A., Rao J. V., Shrinivasu P., Prasad J. V. and Pavani G. (2012). New Stability Indicatingrp-Lc Method For Simultaneous Quantification Of Related Impurities Of Lamivudine, Tenofovir Disoproxil Fumarate And Nevirapine In Extended Release Tablet Dosage Form, Int Research Journals Pharmacy, 3(11), 103–107.
 Sudha T. and Manjeera K. K. (2012). Stability indicating RP-HPLC method for the simultaneous estimation of the anti-retroviral drugs and in tablet dosage forms, International Journal of Biology, Pharmacy and Allied Sciences, 1(9), 1322–1335.
 Rao S., Kumar N., Srilekha K. And Kumari A. (2016). Stability Indicating Method For The Simultaneous Estimation Of Tenofovir, Emtricitabine And Efavirenz In Pure And Pharmaceutical Dosage Form By RPHPLC, International Journal of Advance Research In Science And Engineering, 5(5), 188–200.
 Rao P. P., Reddy D. M. and D. Ramachandran (2014). Stability indicating HPLC method for simultaneous estimation of emtricitabine, tenofovir disoproxyl fumarate, cobicistat and elvitegravir in pharmaceutical dosage form, World Journal of Pharmaceutical Sciences, 2(12), 1822–1829.
 Buridi K. R. (2013). Quantitative Determination of Tenofovirdisproxil Fumarate as an Active PharmaceuticalIngredient in Tablet Formulations by Visible Spectrophotometry, Asian Journal of Pharmaceutical Research and Health Care, 5(1), 24–31.
 Gnanarajan G., Gupta A., Juyal V., Kumar P., Yadav P. and Kailash P. (2009). A validated method for development of tenofovir as API and tablet dosage forms by UV spectroscopy, Journal of Young Pharmacists, 1(4), 351–353. https://doi.org/10.4103/0975-1483.59326
 Balaji M., Moorthy G., Perumal R. V., Sumanth K. S., Channabasavaraj K. P. (2012). Development And Validation of UV spectrophotometric Methods for Quantitative Estimation of Tenofovir Disproxil Fumarate in Bulk & Pharmaceutical Dosage Form, International Journal of Pharmaceutical Research & Analysis, 2(1), 14–17.
 Mondal N. And Singh Y. (2014). Development and Validation of Different Spectrophotometric Methods for Estimation of Tenofovir Disoproxil Fumarate From Bulk Drug and Tablets, International Journal of Pharmaceutical Sciences And Research, 5(2), 623–629.
 Srujani C., Sowmya D. K., Murthy V. S. and Rani A. P. (2015). Development and validation of stability indicating aUVspectrophotometric method for the estimation of tenofovir in its bulk and pharmaceutical dosage form, Pharmacia Lettre, Scholars Research Library, 7(9), 177–185.
 Himaja M., Kalpana J. and Anbarasu C. (2014). Validated zero order and first order derivative spectrophotometric methods for in-vitro analysis of Tenofovir disoproxil fumarate tablets using azeotropic mixture, Int J Pharm Pharm Sci, 6(6), 302–304.
 Rani T. S., Sujatha K., Chitra K., Jacob D., Yandapalli R., Manoj D. and Susma B.: Spectrophotometric methods for estimation of tenofovir disoproxilfumarate in tablet, Res Rev J Pharm Anal, 2012, 1(1), 9–12.
 Viswanath V., Shanmugasundaram P., Ravichandiran V. (2013). UV-Spectrophotometric Absorbance Correction Method for the Simultaneous Estimation of Tenofovir Disoproxil Fumarate and Emtricitabine in Combined Tablet Dosage Form, International Journal of PharmTech Research, 5(3), 1179–1185.
 Sasikala M., Deepthi M. T., Kumar K. V., Raja N.M. (2013). Development And Validation of UV Spectrophotometric Method For The Simultaneous Estimation of Tenofovir Disproxil Fumarate And Emtricitabine In Tablet Dosage Form By Derivative Spectroscopic Method, International Bulletin of Drug Research, 3(5), 20–28.
 Choudhari V. P., Ingale S., Gite S. R., Tajane D. D., Modak V. G. and Ambedkar A. (2011).Spectrophotometric simultaneous determination of Tenofovir disoproxil fumarate and Emtricitabine in combined tablet dosage form by ratio derivative, first order derivative and absorbance corrected methods and its application to dissolution study, Pharmaceutical methods, 2(1), 47–52. https://doi.org/10.4103/2229-4708.81096
 Dr. Srinivasan R., Mary K. L., Lakshmana G., Kumar D. R., Rajini B. (2014). Method development and validation of tenofovir disoprpxilfumarate andemtricitabine in combinedtablet dosage form by UVspectrophotometry and RP-HPLC. Int. J. of Pharmacy and Analytical Research, 3(4), 414–421.
 Ananda kumar K., Kannan K. and Vetrichelvan T.(2011). Development and validation of emtricitabine and tenofovir disoproxilfumarate in pure and in fixed dose combination by UV Spectrophotometry, Digest Journal of Nanomaterials and Biostructures, 6(3), 1085–1090.
 Dubbaka A., Sireesha D., Basha S. A., Talla R., Haque M. A., Harshini S., Vasudha B. (2015). Analytical Method Development and Validation forthe Simultaneous Estimation of Lamivudine and Tenofovir Disoproxil Fumarate in Bulk and Spectrophotometric Method, International Journal of Innovative Pharmaceutical Sciences and Research, 3(10), 1529–1536.
 Soumya B., Kumar T. M. and Raghunandhan N.(2012). Simultaneous determination of Tenofovir disoproxil fumarate and Lamivudine by UV Spectrophotometric Method, International Journal of Pharmacy and Pharmaceutical Science Research, 2(1), 9–15.
 Madhuri M., Sri K. V. And Jain G. V. (2014). Simultaneous Estimation And Validation of Tenofovir Disproxil Fumarate, Emtricitabine And Rilpivirine Hydrochloride In Pharmaceutical Dosage Form By UV-Spectrophotometry, Indo-American Journal of Pharmaceutical Research, 4(12), 5864–5873.
 Liu J. and Duan Y. (2015). Field-Amplified on-line Sample Stacking for Separation and Determination of Adefovir and Tenofovir Using Capillary Electrophoresis, Asian Journal of Chemistry, 27(9), 3143. https://doi.org/10.14233/ajchem.2015.15412
 Jain R. and Sharma, R. (2013). Cathodic adsorptive stripping voltammetric detection and quantification ofthe antiretroviral drug tenofovir in human Plasma and a tablet Formulation, Journal of The Electrochemical Society, 160(8), H489–H493. https://doi.org/10.1149/2.105308jes
 Disha N. S. And Gurupadayya B. M. (2013). Determination of Tenofovir Disoproxil Fumarate an Pharmaceutical Formulations By P-Chloranilic Acid and Sodium Nitroprusside as Reagent. International Journal of Advances in Pharmaceutical Research. 4(9), 2189–2195.
 D’Avolio A., Sciandra M., Siccardi M., Baietto L., de Requena D. G., Bonora S. and Di Perri G. (2008). A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV-infected patients, Journal of chromatographic science, 46(6), 524–528. https://doi.org/10.1093/chromsci/46.6.524
Copyright (c) 2018 Journal of Pharmaceutical Technology, Research and Management
This work is licensed under a Creative Commons Attribution 4.0 International License.
Chitkara University Publications for the Journal of Pharmaceutical Technology, Research And Management (J. Pharm. Technol. Res. Manag.) protects author rights e.g., the results, analysis, methodology of Theoretical calculations or experiment. The copyright transfer form with open access policy under the creative common licenses of journal provides all rights specifically to the author (s); except to sell, distribution of the material in any form to any third party. Also, the authors are encouraged to submit the author’s copy of the accepted paper to an appropriate archive e.g. arxive.org and/or in their institution’s repositories, or on their personal website also.
Authors should mention reference of Chitkara University Publication and DOI number of the publication carefully on the required page of depository, in all above mentioned cases. The copyright and license policy of Chitkara University Publications not only protect the authors rights but also protect the integrity and authenticity of the scientific records and takes very seriously about the plagiarism, fraud or ethics disputes.
Articles in Journal of Pharmaceutical Technology, Research And Management (J. Pharm. Technol. Res. Manag.) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at https://jptrm.chitkara.edu.in. This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.
View Legal Code of the above mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode
View Licence Deed here https://creativecommons.org/licenses/by/4.0/
|Journal of Pharmaceutical Technology, Research And Management by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://jptrm.chitkara.edu.in